Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
Biotech company developing iPSC cell therapies for neurological disorders including stroke and traumatic brain injury.
Hopstem, based in Baltimore, Maryland, Hangzhou, China, and Houston, Texas, develops induced pluripotent stem cell (iPSC) therapies for neurological disorders such as stroke and traumatic brain injury. The company operates a neural differentiation platform and a GMP manufacturing facility, advancing its lead product, hNPC01, a human forebrain neural progenitor cell therapy, through clinical trials. Hopstem has raised $154.5 million in total funding, including a recent $40 million round, and reports fewer than 25 employees with revenue under $5 million. Its hNPC01 therapy recently received FDA clearance to proceed directly to Phase 2 trials in the US, with an adaptive design allowing expansion into a Phase 2/3 pivotal trial. Founded in 2017 by Dr. Jing Fan, the company also targets autism, Alzheimer's disease, and ALS.
Hopstem has raised $40.0M across 1 funding round.
Hopstem has raised $40.0M in total across 1 funding round.
Hopstem has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series B in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2021 | $40M Series B | — | Lilly Asia Ventures | Announced |
Hopstem has raised $40.0M in total across 1 funding round.
Hopstem's investors include Lilly Asia Ventures.